vaccine dose Articles
-
Tackling the Global Vaccine Distribution Challenge
A breakthrough in nanotechnology accelerates vaccine production While COVID-19 hotspots have continued to emerge driven by the Delta variants, the data still shows that vaccinations are effective at preventing hospitalizations and deaths. While over 4 billion vaccine doses have been administered worldwide, only 27% of the world’s population and only 1.1% of people in low-income countries ...
-
Why Vaccines should be Refrigerated
Each vaccine needs to be stored in a cool and refrigerated place to ensure its efficiency and effectiveness are maintained during use. Every year, millions of people are vaccinated to strengthen their immunity and protect themselves from infectious diseases. According to the regulations of the World Health Organization (WHO), vaccination is an approved tool for dealing with deadly contagious ...
By AKCP
-
The Art and Science of Shipping Flu Vaccines
CSL Seqirus delivered a record 135 million doses of flu vaccines globally last year, here’s how we make such a feat happen. Influenza vaccine manufacturing is an intricate and complex process that culminates in the summer months, when U.S. flu vaccine manufacturers receive regulatory approval from the FDA for the season’s vaccines. The manufacturers then prepare to distribute ...
-
The Network that Makes Seasonal Flu Vaccines Possible
Influenza is constantly mutating. 70 years ago, the World Health Organization set up a surveillance network to protect people from its threat. Making influenza vaccines that can help protect against viruses that threaten human health isn’t a simple process. It requires the cooperation between influenza vaccine manufacturers like Seqirus, and the World Health Organization’s ...
-
Could a COVID Vaccine threaten an endangered species and impact human health in the process?
What do you find at the intersection of COVID-19 and endangered species? There is a joke in there somewhere, but if you’re drawing a blank I’ll fill it in for you: horseshoe crabs. Yes, believe it or not, these prehistoric, ocean-dwelling creatures may find themselves on the edge of extinction after a COVID-19 vaccine is mass-produced and distributed worldwide. These large, ...
-
FluGen Announces First Subject Dosed in Phase 1b Clinical Trial of its Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults
Study will measure immune responses generated by M2SR and high dose vaccine separately and in combination in the highly vulnerable 65-85 years old population – Funded by the US Department of Defense, this study is expected to yield topline data in 2H 2022 – MADISON, Wis., June 22, 2022 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine ...
By FluGen, Inc.
-
The race to a vaccine - unintended consequences?
A gold rush is on to find a vaccine for COVID-19. According to the World Health Association (WHO) in early May, there are more than 100 projects around the world centered on the development of a vaccine for the coronavirus. Eight candidate vaccines are already being tested in people in clinical trials. Once an effective vaccine (or vaccines) has been identified, it will need to be produced ...
By Vistex Inc
-
Air Delivery of Super-Cooled COVID-19 Vaccines
There are several potential COVID-19 vaccines that may soon be available for widespread distribution. In particular, the United Kingdom has recently approved Pfizer’s vaccine, and the U.S. Food and Drug Administration is considering extending Emergency Use Authorization to the Pfizer and Moderna vaccines. That is certainly promising news, but storage, transportation, and delivery of these ...
-
FluGen Announces Completion of First Cohort in Age De-escalation Clinical Trial of M2SR Flu Vaccine Candidate in Pediatric Subjects Ages 6 Months to 17 Years
MADISON, Wis., Sept. 7, 2022 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the completion of enrollment of the first cohort in an age de-escalation clinical trial of M2SR (M2 Deficient Single Replication) live virus vaccine, the company’s investigational supra-seasonal intranasal ...
By FluGen, Inc.
-
FluGen Awarded US Department of Defense Funding to Conduct Clinical Study Evaluating Investigational M2SR Flu Vaccine and Current Standard-of-Care High Dose Vaccine
Study is the Company’s first trial evaluating ability of M2SR and the current licensed standard of care to protect against drifted virus strains, and its second study in older adults, a population most vulnerable to mortality from flu – Safety and immunogenicity study expected to begin in Q2 2022 – MADISON, Wis., July 1, 2021 /PRNewswire/ — FluGen, Inc., a clinical-stage ...
By FluGen, Inc.
-
Host Cell Residual DNA: Understanding its Significance and Detection Methods
Host Cell Residual DNA (rcDNA) refers to fragments of DNA derived from host cells that may be present in biological products. These products must not contain foreign substances, particularly host DNA, to avoid immune rejection and potential threats to life safety. Regulatory agencies worldwide have imposed strict limits on the amount of rcDNA, and various pharmacopoeias have outlined several ...
-
Your Herd Vaccinations May not Always be Successful? Why?
We hear a lot about how to protect yourself and others right now… and it is especially important to me because I am in a high-risk group (over 65 with underlining health conditions). In the Dairy Industry, we deal with high-risk groups every day–cows that have just calved and newborn calves less than 75 days of age. Herd immunity threshold (percent of animals that are immune) ...
-
As Covid-19 Continues, US has Made Progress in Reducing Cases and Vaccinating the Public
At the beginning of this year, the US saw the highest number of Covid-19 cases and deaths it had ever seen. Personal protection equipment (PPE), like masks and gloves, was next to impossible to find and purchase resulting in the worst shortage since the start of the pandemic. On top of a PPE shortage, price gouging and supply chain disruption shook US businesses to their core. 2021 was off to a ...
-
The Future of COVID-19 and Vaccinations
Coronavirus 2021 COVID-19 is nearing the one-year mark in the United States with over 26.2 million cases to date. While cases in the United States are still doubling their daily totals, many people worldwide are experiencing pandemic fatigue. Just before the end of 2020, companies like Moderna and Pfizer, with help from many C & A Scientific customers, were able to provide a solution ...
-
A Bayesian design for phase I cancer therapeutic vaccine trials
Abstract Phase I clinical trials are the first step in drug development to test a new drug or drug combination on humans. Typical designs of Phase I trials use toxicity as the primary endpoint and aim to find the maximum tolerable dosage. However, these designs are poorly applicable for the development of cancer therapeutic vaccines because the expected safety concerns for these vaccines are not ...
-
FluGen Announces Publication of Positive Results from Phase 2 Human Challenge Study of Its M2SR Vaccine Candidate Against Highly Drifted Strain of H3N2 Influenza Virus
Data published in the Journal of Infectious Diseases demonstrate that M2SR can protect against a multi-seasonal, seven-year drifted influenza strain – MADISON, Wis., Aug. 2, 2021 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced the publication of results from its Phase 2 human challenge ...
By FluGen, Inc.
-
Duration of protection from live attenuated vs. sub unit HSV-2 vaccines in the guinea pig model of genital herpes: Reassessing efficacy using endpoints from clinical trials
Abstract Background Although herpes simplex viruses (HSV) are a major target for vaccine development no vaccine is currently licensed. Methods A live attenuated HSV virus vaccine, VC2 was compared to a subunit HSV vaccine, glycoprotein D (gD2) administered with the adjuvant, MPL/Alum using the guinea pig model of genital herpes. Three doses of intramuscular (IM) vaccine were provided followed by ...
-
mRNA vaccine for the pregnant produces antibodies that are passed on to the child and remain for at least 6 months
As the COVID-19 pandemic enters its third year, efforts to mitigate the risk of infection remain critical, especially for vulnerable populations. Recently, Andrea Edlow et al. of Massachusetts General Hospital published a study in the journal JAMA entitled "Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural Infection". The study showed that ...
-
Vaccine Manufacturing – how will supply chain complexity effect a distributed vaccine manufacturing network?
As of October 2021, 6-7 billion doses of COVID-19 vaccines have been provided under emergency measures. The vaccines roll out has peaked at 45 million doses/day and has remained broadly stable (Our Word in Data & WHO), so we can assume that this is the current global manufacturing capacity. But with only 35% of the worlds’ population fully vaccinated, we must also assume, along with ...
-
Evolution of Anti-SARS-CoV-2 IgG Antibody and IgG Avidity Post Pfizer and Moderna mRNA Vaccinations
Abstract Messenger RNA (mRNA) based vaccines (Pfizer/BioNTech and Moderna) are highly effective at providing immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there is uncertainty about the duration of immunity, evolution of IgG antibody levels and IgG avidity (an index of antibody-antigen binding strength), and differences in the immune responses between ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you